BACKGROUND: X-linked agammaglobulinemia is an inherited immunodeficiency recognized since 1952. In spite of seven decades of experience, there is still a limited understanding of regional differences in presentation and complications. This study was designed by the Primary Immunodeficiencies Committee of the World Allergy Organization to better understand regional needs, challenges and unique patient features. METHODS: A survey instrument was designed by the Primary Immunodeficiencies Committee of the World Allergy Organization to collect both structured and semi-structured data on X-linked agammaglobulinemia. The survey was sent to 54 centers around the world chosen on the basis of World Allergy Organization participation and/or registration in the European Society for Immunodeficiencies. There were 40 centers that responded, comprising 32 countries. RESULTS: This study reports on 783 patients from 40 centers around the world. Problems with diagnosis are highlighted by the reported delays in diagnosis>24 months in 34% of patients and the lack of genetic studies in 39% of centers Two infections exhibited regional variation. Vaccine-associated paralytic poliomyelitis was seen only in countries with live polio vaccination and two centers reported mycobacteria. High rates of morbidity were reported. Acute and chronic lung diseases accounted for 41% of the deaths. Unusual complications such as inflammatory bowel disease and large granular lymphocyte disease, among others were specifically enumerated, and while individually uncommon, they were collectively seen in 20.3% of patients. These data suggest that a broad range of both inflammatory, infectious, and autoimmune conditions can occur in patients. The breadth of complications and lack of data on management subsequently appeared as a significant challenge reported by centers. Survival above 20 years of age was lowest in Africa (22%) and reached above 70% in Australia, Europe and the Americas. Centers were asked to report their challenges and responses (n = 116) emphasized the difficulties in access to immunoglobulin products (16%) and reflected the ongoing need for education of both patients and referring physicians. CONCLUSIONS: This is the largest study of patients with X-linked agammaglobulinemia and emphasizes the continued morbidity and mortality of XLA despite progress in diagnosis and treatment. It presents a world view of the successes and challenges for patients and physicians alike. A pivotal finding is the need for education of physicians regarding typical symptoms suggesting a possible diagnosis of X-linked agammaglobulinemia and sharing of best practices for the less common complications.

Ankara University School of Medicine Department of Pediatric Immunology and Allergy Ankara Turkey

Centre for Primary Immunodeficiency Department of Pediatric Pulmonology and Immunology Ghent University Hospital Belgium

Clinical Immunology Unit P1 Ibn Rushd Hospital Laboratoire d'Immunologie Clinique Inflammation et Allergie LICIA and Medicine and Pharmacy Faculty of Hassan 2 University Casablanca Morocco

Dalhousie University IWK Health Centre Halifax Nova Scotia Canada

Department of Allergy and Immunology The Royal Children's Hospital Melbourne Australia

Department of Child Health and Development Graduate School of Medical and Dental Sciences Tokyo Medical and Dental University Tokyo Japan

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czech Republic

Department of Immunology Institut Pasteur d'Algérie Faculty of Medicine Algiers Algeria

Department of Immunology Institute of Biomedical Sciences University of Sao Paulo Sao Paulo Sp Brazil

Department of Immunology National Medical and Research Center for Pediatric Hematology Oncology and Immunology Moscow Russia

Department of Medicine and Sciences of Aging University G d'Annunzio of Chieti Pescara Italy

Department of Microbiology Parasitology and Immunology Faculty of Medicine University of Khartoum Sudan

Department of Paediatrics and Adolescent Medicine Queen Mary Hospital The University of Hong Kong Hong Kong China

Department of Pediatric and Child Health Aga Khan University Hospital Karachi Pakistan

Department of Pediatric Hematology Oncology Super Speciality Pediatric Hospital and PG Teaching Institute Noida India

Department of Pediatric Infectious Diseases and Immunology Shupyk National Medical Academy of Postgraduate Education and Center for Clinical Immunology City Children's Hospital N1 Kiev Ukraine

Department of Pediatrics and Chief Allergy Immunology Unit Advanced Pediatrics Centre Post Graduate Institute of Medical Education and Research Chandigarh India

Department of Pediatrics Faculty of Medicine Cairo University Egypt

Department of Pediatrics Faculty of Medicine Kuwait University Allergy and Clinical Immunology Unit Al Sabah Hospital Kuwait City Kuwait

Department of Translational Medical Sciences Section of Pediatrics Federico 2 University Naples Italy

Division of Allergy and Clinical Immunology Department of Pediatrics Medical College of Wisconsin Milwaukee WI USA

Division of Allergy Immunology Department of Pediatrics The Children's Hospital of Philadelphia Philadelphia PA USA

Division of Pediatric Infectious Diseases and Center for Infectious Diseases Research Department of Pediatrics and Adolescent Medicine American University of Beirut Beirut Lebanon

Federal University of Parana Curitiba Brazil

Hospital HHA Universidad de la Frontera Temuco Chile

Immunology Unit Hospital de Niños Ricardo Gutiérrez and CIC CABA Buenos Aires Argentina

LSU Health Sciences Center New Orleans LA USA

Murdoch Children's Research Institute Melbourne Australia

Paediatric Infectious Diseases Unit Red Cross War Memorial Children's Hospital and the Department of Paediatrics and Child Health University of Cape Town Cape Town South Africa

Paediatric Institute Kuala Lumpur General Hospital Kuala Lumpur Malaysia

Pediatric Allergy and Immunology Unit Children's Hospital Ain Shams University Cairo Egypt

Pediatric Immuno hematology Unit Bone Marrow Transplantation Center University Tunis El Manar Faculty of Medicine Tunis Tunisia

Pediatric Immunopathology and Allergology Unit Tor Vergata University Hospital University of Rome Tor Vergata Rome Italy

Pediatrics Clinic and Institute for Molecular Medicine A Nocivelli Department of Clinical and Experimental Sciences University of Brescia and ASST Spedali Civili of Brescia Brescia Italy

Primary Immunodeficiencies Unit Hospital Dona Estefânia Centro Hospitalar de Lisboa Central and CEDOC Nova Medical School Lisboa Portugal

Primary Immunodeficiency Research Lab Ghent University Belgium

Primary Immunodeficiency Unit Allergy and Immunology Division Hospital Nacional Edgardo Rebagliati Martins Lima Peru

Rare Diseases Center Children's Hospital and Adult Immunodeficiency Unit Infectious Diseases Inflammation Center University of Helsinki and Helsinki University Hospital Helsinki Finland

Research Center for Immunodeficiencies Children's Medical Center Tehran University of Medical Sciences and Network of Immunity in Infection Malignancy and Autoimmunity Tehran Iran

Servicio de Inmunología Hospital Universitario Virgen del Rocío Seville Spain

The Immunodeficiencies Research Unit National Institute of Pediatrics Mexico City Mexico

The Royal Hospitals and Queen's University Belfast United Kingdom

The University of Melbourne Australia

University Department of Pediatrics Unit of Immune and Infectious Diseases Childrens' Hospital Bambino Gesù University of Rome Tor Vergata Rome Italy

Zobrazit více v PubMed

Tsukada S., Saffran D.C., Rawlings D.J. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279–290. PubMed

Vetrie D., Vorechovsky I., Sideras P. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226–233. PubMed

Conley M.E., Cooper M.D. Genetic basis of abnormal B cell development. Curr Opin Immunol. 1998;10(4):399–406. PubMed

Conley M.E., Mathias D., Treadaway J., Minegishi Y., Rohrer J. Mutations in btk in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet. 1998;62(5):1034–1043. PubMed PMC

Alvarez-Marquez A., Abad- Molina C., Montes-Cano M., Nunez-Roldan A., Sanchez B. Analysis of Bruton's tyrosine kinase deficiency in patients with presumed X-linked agammaglobulinemia. J Clin Exp Immunol. 2018;3(1):1–2.

Kanegane H., Futatani T., Wang Y. Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis. J Allergy Clin Immunol. 2001;108(6):1012–1020. PubMed

Moschese V., Orlandi P., Plebani A. X-chromosome inactivation and mutation pattern in the Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinemia. Italian XLA collaborative group. Mol Med. 2000;6(2):104–113. PubMed PMC

Aadam Z., Kechout N., Barakat A. X-linked agammagobulinemia in a large series of North African patients: frequency, clinical features and novel BTK mutations. J Clin Immunol. 2016;36(3):187–194. PubMed

Ben-Ali M., Yang J., Chan K.W. Homozygous transcription factor 3 gene (TCF3) mutation is associated with severe hypogammaglobulinemia and B-cell acute lymphoblastic leukemia. J Allergy Clin Immunol. 2017;140(4):1191–1194. e4. PubMed

Conley M.E., Dobbs A.K., Farmer D.M. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol. 2009;27:199–227. PubMed

Boisson B., Wang Y.D., Bosompem A. A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(-) B cells. J Clin Invest. 2013;123(11):4781–4785. PubMed PMC

Sawada A., Takihara Y., Kim J.Y. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J Clin Invest. 2003;112(11):1707–1713. PubMed PMC

Vihinen M., Kwan S.P., Lester T. Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia. Hum Mutat. 1999;13(4):280–285. PubMed

Winkelstein J.A., Marino M.C., Lederman H.M. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85(4):193–202. PubMed

Ryser O., Morell A., Hitzig W.H. Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children. J Clin Immunol. 1988;8(6):479–485. PubMed

Matamoros Flori N., Mila Llambi J., Espanol Boren T., Raga Borja S., Fontan Casariego G. Primary immunodeficiency syndrome in Spain: first report of the national registry in children and adults. J Clin Immunol. 1997;17(4):333–339. PubMed

Stray-Pedersen A., Abrahamsen T.G., Froland S.S. Primary immunodeficiency diseases in Norway. J Clin Immunol. 2000;20(6):477–485. PubMed

Lederman H.M., Winkelstein J.A. X-linked agammaglobulinemia: an analysis of 96 patients. Medicine (Baltimore) 1985;64(3):145–156. PubMed

Chun J.K., Lee T.J., Song J.W., Linton J.A., Kim D.S. Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at Severance Hospital. Yonsei Med J. 2008;49(1):28–36. PubMed PMC

Bearden D., Collett M., Quan P.L., Costa-Carvalho B.T., Sullivan K.E. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016;4(6):1059–1065. PubMed

Jacobs Z.D., Guajardo J.R., Anderson K.M. XLA-associated neutropenia treatment: a case report and review of the literature. J Pediatr Hematol Oncol. 2008;30(8):631–634. PubMed

Singh S., Rawat A., Suri D. X-linked agammaglobulinemia: twenty years of single-center experience from North West India. Ann Allergy Asthma Immunol. 2016;117(4):405–411. PubMed

Hernandez-Trujillo V.P., Scalchunes C., Cunningham-Rundles C. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol. 2014;34(6):627–632. PubMed PMC

Plebani A., Soresina A., Rondelli R. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–230. PubMed

Chen X.F., Wang W.F., Zhang Y.D., Zhao W., Wu J., Chen T.X. Clinical characteristics and genetic profiles of 174 patients with X-linked agammaglobulinemia: report from Shanghai, China (2000-2015) Medicine (Baltimore) 2016;95(32) PubMed PMC

Soresina A., Nacinovich R., Bomba M. The quality of life of children and adolescents with X-linked agammaglobulinemia. J Clin Immunol. 2009;29(4):501–507. PubMed

Moschese V., Martire B., Soresina A. Anti-infective prophylaxis for primary immunodeficiencies: what is done in Italian Primary Immunodeficiency Network centers (IPINet) and review of the literature. J Biol Regul Homeost Agents. 2013;27(4):935–946. PubMed

Perez E.E., Orange J.S., Bonilla F. Update on the use of immunoglobulin in human disease: a review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1–S46. PubMed

Orange J.S., Grossman W.J., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30. PubMed

Albin S., Cunningham-Rundles C. An update on the use of immunoglobulin for the treatment of immunodeficiency disorders. Immunotherapy. 2014;6(10):1113–1126. PubMed PMC

Bonilla F.A., Khan D.A., Ballas Z.K. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136(5):1186–11205. e1-78. PubMed

Weber A.N.R., Bittner Z., Liu X., Dang T.M., Radsak M.P., Brunner C. Bruton's tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454. PubMed PMC

Bao Y., Zheng J., Han C. Tyrosine kinase Btk is required for NK cell activation. J Biol Chem. 2012;287(28):23769–23778. PubMed PMC

Schmidt N.W., Thieu V.T., Mann B.A., Ahyi A.N., Kaplan M.H. Bruton's tyrosine kinase is required for TLR-induced IL-10 production. J Immunol. 2006;177(10):7203–7210. PubMed

Cavaliere F.M., Prezzo A., Bilotta C., Iacobini M., Quinti I. The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement. PLoS One. 2017;12(4) PubMed PMC

Mirsafian H., Ripen A.M., Leong W.M., Chear C.T., Bin Mohamad S., Merican A.F. Transcriptome profiling of monocytes from XLA patients revealed the innate immune function dysregulation due to the BTK gene expression deficiency. Sci Rep. 2017;7(1):6836. PubMed PMC

Kubo T., Uchida Y., Watanabe Y. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med. 2009;206(9):1971–1982. PubMed PMC

Liu X., Zhan Z., Li D. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011;12(5):416–424. PubMed

Fadlallah J., El Kafsi H., Sterlin D. Microbial ecology perturbation in human IgA deficiency. Sci Transl Med. 2018;10(439) PubMed

Sokol H., Mahlaoui N., Aguilar C. Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. J Allergy Clin Immunol. 2018;143:775–778. PubMed

Diagnostic Criteria for PID. 2018. https://esid.org/Working-Parties/Clinical-Working-Party/Resources/Diagnostic-criteria-for-PID2 Available from:

Ariganello P., Angelino G., Scarselli A. Relapsing Campylobacter jejuni systemic infections in a child with X-linked agammaglobulinemia. Case Rep Pediatr. 2013;2013:735108. PubMed PMC

Pac M., Bernatowska E.A., Kierkus J. Gastrointestinal disorders next to respiratory infections as leading symptoms of X-linked agammaglobulinemia in children - 34-year experience of a single center. Arch Med Sci. 2017;13(2):412–417. PubMed PMC

Boushaki S., Tahiat A., Meddour Y. Prevalence of BTK mutations in male Algerian patterns with agammaglobulinemia and severe B cell lymphopenia. Clin Immunol. 2015;161(2):286–290. PubMed

Mohammadinejad P., Pourhamdi S., Abolhassani H. Primary antibody deficiency in a tertiary referral hospital: a 30-year experiment. J Investig Allergol Clin Immunol. 2015;25(6):416–425. PubMed

Bazregari S., Azizi G., Tavakol M. Evaluation of infectious and non-infectious complications in patients with primary immunodeficiency. Cent Eur J Immunol. 2017;42(4):336–341. PubMed PMC

Quartier P., Debre M., De Blic J. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Pediatr. 1999;134(5):589–596. PubMed

Van der Hilst J.C., Smits B.W., van der Meer J.W. Hypogammaglobulinaemia: cumulative experience in 49 patients in a tertiary care institution. Neth J Med. 2002;60(3):140–147. PubMed

Fernandes A., Guedes M., Vasconcelos J., Neves E., Fernandes S., Marques L. X-linked agammaglobulinemia: experience in a Portuguese hospital. An Pediatr (Barc) 2015;82(3):166–171. PubMed

Lopez-Granados E., Perez de Diego R., Ferreira Cerdan A., Fontan Casariego G., Garcia Rodriguez M.C. A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia. J Allergy Clin Immunol. 2005;116(3):690–697. PubMed

Hansel T.T., Haeney M.R., Thompson R.A. Primary hypogammaglobulinaemia and arthritis. Br Med J (Clin Res Ed). 1987;295(6591):174–175. PubMed PMC

Garcia-Garcia E., Staines-Boone A.T., Vargas-Hernandez A. Clinical and mutational features of X-linked agammaglobulinemia in Mexico. Clin Immunol. 2016;165:38–44. PubMed

Bruton O.C. Agammaglobulinemia (congenital absence of gamma globulin); report of a case. Med Ann D C. 1953;22(12):648–650. PubMed

Bruton O.C. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728. PubMed

Suri D., Bhattad S., Sharma A. Serial serum immunoglobulin G (IgG) trough levels in patients with X-linked agammaglobulinemia on replacement therapy with intravenous immunoglobulin: its correlation with infections in Indian children. J Clin Immunol. 2017;37(3):311–318. PubMed

Eurordis . 2008. The Voice of 12,000 Patients.http://www.eurordis.org/publication/voice-12000-patients

Condino-Neto A., Espinosa-Rosales F. Changing the lives of people with primary immunodeficiencies (PI) with early testing and diagnosis. Front Immunol. 2018 June:1439. PubMed PMC

Costa-Carvalho B.T., Grumach A.S., Franco J.L. Attending to warning signs of primary immunodeficiency diseases across the range of clinical practice. J Clin Immunol. 2014;34(1):10–22. PubMed PMC

Cuccherini B., Chua K., Gill V. Bacteremia and skin/bone infections in two patients with X-linked agammaglobulinemia caused by an unusual organism related to Flexispira/Helicobacter species. Clin Immunol. 2000;97(2):121–129. PubMed

Bloom K.A., Chung D., Cunningham-Rundles C. Osteoarticular infectious complications in patients with primary immunodeficiencies. Curr Opin Rheumatol. 2008;20(4):480–485. PubMed PMC

Hermaszewski R.A., Webster A.D. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med. 1993;86(1):31–42. PubMed

Franz A., Webster A.D., Furr P.M., Taylor-Robinson D. Mycoplasmal arthritis in patients with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. Br J Rheumatol. 1997;36(6):661–668. PubMed

Foundation ID . 2017. Transition Guide.https://primaryimmune.org/sites/default/files/publications/IDF-Transition-Guide-Pediatric-to-Adult-Care-FINAL.pdf Available from:

Hagood J.S., Lenker C.V., Thrasher S. A course on the transition to adult care of patients with childhood-onset chronic illnesses. Acad Med. 2005;80(4):352–355. PubMed

Lotstein D.S., Ghandour R., Cash A., McGuire E., Strickland B., Newacheck P. Planning for health care transitions: results from the 2005-2006 national survey of children with special health care needs. Pediatrics. 2009;123(1):e145–e152. PubMed

Organization WH . 2017. WHO Model List of Essential Medicines for Children.http://www.who.int/medicines/publications/essentialmedicines/6th_EMLc2017_FINAL_amendedAug2017.pdf?ua=1 Available from:

Self-reported Clinical Outcomes and Quality of Life in Agammaglobulinemia: the Importance of an Early Diagnosis